Genetic Technologies (ASX:GTG) joined the Chicago-based CancerIQ platform, giving it access to the US healthcare system, according to a Wednesday filing with the Australian bourse.
As part of the move, Genetic Technologies will pay an annual fee of $75,000 to access CancerIQ's premium tier, the filing stated. This will give the molecular diagnostics company an entry point to over 45 health systems and 250 clinics in the US that are part of CancerIQ's platform.
The partnership includes the addition of Genetic Technologies' geneType risk assessment test portfolio to support CancerIQ's expansion into primary preventive care.
Genetic Technologies' shares were up nearly 8% in recent trade.
Price (AUD): $0.04, Change: $+0.0030, Percent Change: +7.50%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.